Key facts
- Ceva Santé Animale’s last known valuation is $9.7B (Mar 2025).
- It has raised $12.6B; the latest was Buyout/LBO in May 2025.
- Notable investors include Temasek Holdings, Sagard, Societe Generale Capital Partenaires, EMZ Partners, Sofiproteol — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Ceva Santé Animale
- ·The full record, as it builds
Funding rounds
No funding rounds for Ceva Santé Animale are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ceva Santé Animale
Manufacturer of veterinary pharmaceutical products intended to be used for companion and production animals. The company offers products for cardiology, behavior and locomotion, and swine and ruminants, as well as for antibiotic therapy, poultry vaccines, vaccination equipment, pharmaceuticals and disinfectants, thereby helping concerned authorities to protect the health of humans and animals.
- Sector
- Materials and Resources
- HQ
- Libourne, France
- Founded
- 1999
- Employees
- 7,200
- Website
- ceva.com/
- Ownership
- Privately Held (backing)
Ceva Santé Animale doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ceva Santé Animale shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ceva Santé Animale in its N-PORT filings yet. We sweep new filings monthly.